TFF Pharmaceuticals announces its new partnership with Emory University and the Biomedical Advanced Research and Development Authority, BARDA. Under the partnership, TFF Pharmaceuticals will test the feasibility of converting Emory’s mRNA-based Cas13a antiviral against influenza A and B and SARS-CoV-2 into a dry powder formulation for more precise inhalational delivery, improved stability and widespread distribution without the need for cold-chain storage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF Pharmaceuticals announces preclinical data from influenza vaccine candidates
- TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
- TFFP Upcoming Earnings Report: What to Expect?
- TFF Pharmaceuticals Shares Update on Recent Developments
- TFF Pharmaceuticals provides continued positive outfomes from TFF TAC